Related Experiment Video
Updated: Oct 19, 2025
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Scalable Manufacturing of CAR T cells for Cancer Immunotherapy
Mohamed Abou-El-Enein1,2, Magdi Elsallab2, Steven A Feldman3
1Division of Medical Oncology, Department of Medicine, and Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. abouelenein@med.usc.edu.
Abstract:
As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T cell therapies for hematological malignancies. With the current transition of CAR T cell manufacturing from academia to industry, there is a shift toward Good Manufacturing Practice (GMP)-compliant closed and automated systems to ensure reproducibility and to meet the increased demand for cancer patients. In this review we describe current CAR T cells clinical manufacturing models and discuss emerging technological advances that embrace scaling and production optimization. We summarize measures being used to shorten CAR T-cell manufacturing times and highlight regulatory challenges to scaling production for clinical use.
Statement Of Significance ∣:
As the demand for CAR T cell cancer therapy increases, several closed and automated production platforms are being deployed, and others are in development.This review provides a critical appraisal of these technologies that can be leveraged to scale and optimize the production of next generation CAR T cells.
Insights
Chimeric antigen receptor (CAR) T cell therapy manufacturing is shifting to automated systems to meet rising demand for cancer patients. This review covers production models, optimization technologies, and regulatory hurdles for scaling CAR T cell therapies.
Area of Science:
- Cellular immunotherapy
- Hematological malignancies
- Biotechnology
Background:
- Five chimeric antigen receptor (CAR) T cell therapies are approved for blood cancers as of April 2021.
- CAR T cell therapy manufacturing is transitioning from academic settings to industrial production.
- There is a growing demand for CAR T cell therapies from cancer patients.
Purpose of the Study:
- To review current clinical manufacturing models for CAR T cells.
- To discuss technological advancements for scaling and optimizing CAR T cell production.
- To summarize strategies for reducing manufacturing times and identify regulatory challenges.
Main Methods:
- Literature review of current CAR T cell manufacturing practices.
- Analysis of emerging technologies for closed and automated systems.
- Discussion of regulatory considerations for large-scale clinical use.
Main Results:
- Shift towards Good Manufacturing Practice (GMP)-compliant closed and automated systems is evident.
- Various technologies are being deployed or developed to scale CAR T cell production.
- Efforts are underway to shorten manufacturing timelines and address scalability issues.
Conclusions:
- Automated and closed manufacturing systems are crucial for reproducible and scalable CAR T cell production.
- Technological innovation is key to optimizing production and meeting patient demand.
- Overcoming regulatory challenges is essential for widespread clinical application of CAR T cell therapies.
